Loading...

Mirati Therapeutics

DB:26M
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
26M
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
26M Share Price and Events
7 Day Returns
4.5%
DB:26M
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
125.5%
DB:26M
-5.6%
DE Biotechs
-4.5%
DE Market
26M Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mirati Therapeutics (26M) 4.5% -15.7% -3.2% 125.5% 203.8% 314.7%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 26M outperformed the Biotechs industry which returned -5.6% over the past year.
  • 26M outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
26M
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Mirati Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mirati Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €56.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mirati Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mirati Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:26M PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.19
NasdaqGS:MRTX Share Price ** NasdaqGS (2019-04-25) in USD $63.91
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mirati Therapeutics.

DB:26M PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MRTX Share Price ÷ EPS (both in USD)

= 63.91 ÷ -3.19

-20.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mirati Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Mirati Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mirati Therapeutics's expected growth come at a high price?
Raw Data
DB:26M PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
17%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mirati Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mirati Therapeutics's assets?
Raw Data
DB:26M PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.19
NasdaqGS:MRTX Share Price * NasdaqGS (2019-04-25) in USD $63.91
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:26M PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MRTX Share Price ÷ Book Value per Share (both in USD)

= 63.91 ÷ 6.19

10.32x

* Primary Listing of Mirati Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mirati Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Mirati Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mirati Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mirati Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mirati Therapeutics expected to grow at an attractive rate?
  • Mirati Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mirati Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Mirati Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:26M Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:26M Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 17%
DB:26M Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 66.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:26M Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:26M Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 615 111 43 9
2022-12-31 324 -126 -31 9
2021-12-31 91 -172 -161 10
2020-12-31 2 -145 -167 12
2019-12-31 1 -118 -140 12
DB:26M Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 13 -70 -98
2018-09-30 9 -63 -88
2018-06-30 9 -58 -77
2018-03-31 9 -54 -67
2017-12-31 -65 -70
2017-09-30 -67 -72
2017-06-30 -70 -75
2017-03-31 -69 -79
2016-12-31 -68 -83
2016-09-30 -68 -82
2016-06-30 -65 -81
2016-03-31 -58 -75

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mirati Therapeutics's earnings are expected to grow by 17% yearly, however this is not considered high growth (20% yearly).
  • Mirati Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:26M Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Mirati Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:26M Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.79 12.04 0.66 6.00
2022-12-31 -0.33 5.02 -5.90 9.00
2021-12-31 -4.02 -1.82 -5.83 11.00
2020-12-31 -4.69 -3.78 -6.10 12.00
2019-12-31 -4.17 -3.74 -5.41 12.00
DB:26M Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.19
2018-09-30 -2.99
2018-06-30 -2.78
2018-03-31 -2.55
2017-12-31 -2.78
2017-09-30 -3.07
2017-06-30 -3.38
2017-03-31 -3.76
2016-12-31 -4.20
2016-09-30 -4.17
2016-06-30 -4.30
2016-03-31 -4.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mirati Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Mirati Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mirati Therapeutics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mirati Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mirati Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mirati Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mirati Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mirati Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mirati Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mirati Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:26M Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.93 -98.42 21.68 93.87
2018-09-30 9.47 -88.04 18.29 82.36
2018-06-30 9.47 -76.82 16.10 72.21
2018-03-31 9.47 -67.29 14.91 63.35
2017-12-31 -70.43 13.45 58.09
2017-09-30 -72.26 14.37 56.29
2017-06-30 -75.33 14.72 58.92
2017-03-31 -79.05 14.86 62.40
2016-12-31 -83.12 15.29 68.49
2016-09-30 -81.81 14.97 67.45
2016-06-30 -81.13 15.65 65.91
2016-03-31 -74.52 16.11 58.74
2015-12-31 -64.54 15.76 48.96
2015-09-30 -56.51 15.55 41.12
2015-06-30 -46.39 15.05 33.45
2015-03-31 -41.98 13.79 29.32
2014-12-31 -43.70 12.70 26.07
2014-09-30 -44.54 11.87 23.32
2014-06-30 -65.32 11.94 21.92
2014-03-31 -62.30 11.34 19.28
2013-12-31 -52.86 11.18 19.80
2013-09-30 -47.93 10.01 20.45
2013-06-30 -24.48 8.00 19.21
2013-03-31 -21.15 6.70 18.57
2012-12-31 -20.29 5.42 15.08
2012-09-30 0.48 -17.54 5.04 13.20
2012-06-30 0.64 -14.83 4.59 11.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mirati Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mirati Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mirati Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mirati Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mirati Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mirati Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mirati Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mirati Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mirati Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mirati Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Mirati Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mirati Therapeutics Company Filings, last reported 3 months ago.

DB:26M Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 201.58 0.00 224.63
2018-09-30 225.09 0.00 243.90
2018-06-30 246.34 0.00 261.26
2018-03-31 137.84 0.00 149.98
2017-12-31 143.29 0.00 152.44
2017-09-30 68.15 0.00 75.73
2017-06-30 82.97 0.00 88.69
2017-03-31 99.12 0.00 106.19
2016-12-31 48.31 0.00 57.49
2016-09-30 65.48 0.00 73.82
2016-06-30 82.18 0.00 91.31
2016-03-31 101.65 0.00 107.67
2015-12-31 118.18 0.00 122.88
2015-09-30 133.86 0.00 138.01
2015-06-30 54.72 0.00 58.88
2015-03-31 67.05 0.00 68.02
2014-12-31 28.06 0.00 29.93
2014-09-30 35.74 0.00 37.71
2014-06-30 4.83 0.00 47.42
2014-03-31 13.59 0.00 53.38
2013-12-31 25.89 0.00 62.07
2013-09-30 -23.56 0.00 15.03
2013-06-30 6.24 0.00 20.26
2013-03-31 14.47 0.00 29.50
2012-12-31 34.42 0.00 36.98
2012-09-30 15.38 0.00 17.60
2012-06-30 19.93 0.00 21.11
  • Mirati Therapeutics has no debt.
  • Mirati Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mirati Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Mirati Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 2.1% each year.
X
Financial health checks
We assess Mirati Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mirati Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mirati Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mirati Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Mirati Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mirati Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mirati Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:26M Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:26M Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mirati Therapeutics has not reported any payouts.
  • Unable to verify if Mirati Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mirati Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mirati Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mirati Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Mirati Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mirati Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mirati Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mirati Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Charles Baum
COMPENSATION $1,622,521
AGE 60
TENURE AS CEO 6.4 years
CEO Bio

Dr. Charles M. Baum, M.D., Ph.D. has been a Director at Immunomedics, Inc. since February 23, 2019. He has been the Chief Executive Officer and President of Mirati Therapeutics, Inc. and MethylGene Inc. since November 12, 2012. Dr. Baum served as Senior Vice President for Clinical Research within Pfizer's Worldwide Research & Development division. Dr. Baum worked at Pfizer since 2003, served on roles of increasing responsibility, including Vice President and Head of Oncology Development and Chief Medical Officer for Pfizer's Biotherapeutics and Bioinnovation Center, a Pfizer division comprised of small biotech research units. From 2000 to 2003, he was responsible for the development of several oncology compounds at Schering-Plough Corporation (acquired by Merck & Co.). During his tenure at Pfizer he was responsible for the development of the oncology portfolio, including the tyrosine kinase inhibitors sunitinib (Sutent(R)), axitinib (Inlyta(R)) and crizotinib (Xalkori(R)). Dr. Baum has important industry and executive-level experience. Dr. Baum has experience with later stage drug development in the field of oncology and has general industry knowledge. His career has included academic and hospital positions at Stanford University and Emory University, as well as positions of increasing responsibility within the pharmaceutical industry at SyStemix, Inc. (acquired by Novartis AG), G.D. Searle & Company (acquired by Pfizer), Schering-Plough Corporation and Pfizer. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide (Temodar(R)). His career also includes academic and hospital positions at Stanford and Emory Universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfizer). He has been an Independent Director of Array BioPharma Inc. since April 25, 2014. He has been a Director of MethylGene Inc. and Mirati Therapeutics, Inc. since November 12, 2012. He was granted research support by the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications. Dr. Baum received his M.D. and Ph.D. (Immunology) degrees from the Washington University School of Medicine and did his post-graduate work at Stanford University, where he completed his medical training and conducted research on human bone marrow stem cells. He completed his Post-doctoral work and residency at Stanford University, California.

CEO Compensation
  • Charles's compensation has been consistent with company performance over the past year.
  • Charles's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Mirati Therapeutics management team in years:

3.1
Average Tenure
53
Average Age
  • The tenure for the Mirati Therapeutics management team is about average.
Management Team

Charles Baum

TITLE
President
COMPENSATION
$2M
AGE
60
TENURE
6.4 yrs

James Christensen

TITLE
Chief Scientific Officer & Executive VP
COMPENSATION
$691K
AGE
50
TENURE
5.3 yrs

Isan Chen

TITLE
Executive VP and Chief Medical & Development Officer
COMPENSATION
$754K
AGE
56
TENURE
5.6 yrs

Jamie Donadio

TITLE
Senior VP & CFO
AGE
43
TENURE
3.1 yrs

Temre Johnson

TITLE
Director of Investor Relations & Corporate Communications

Perry Johnston

TITLE
Chief Legal & Compliance Officer
AGE
55

Chris LeMasters

TITLE
Chief Business Officer & Executive VP
AGE
51
TENURE
2.6 yrs

Sanjeev Sharma

TITLE
Senior Vice President of CMC & Product Development
TENURE
1.8 yrs

Matthew Marx

TITLE
VP & Head of Drug Discovery
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Mirati Therapeutics board of directors in years:

5.6
Average Tenure
60.5
Average Age
  • The tenure for the Mirati Therapeutics board of directors is about average.
Board of Directors

Faheem Hasnain

TITLE
Chairman of the Board
AGE
60
TENURE
0.2 yrs

Charles Baum

TITLE
President
COMPENSATION
$2M
AGE
60
TENURE
6.4 yrs

Hank Fuchs

TITLE
Independent Director
COMPENSATION
$78K
AGE
60
TENURE
7.2 yrs

Craig Johnson

TITLE
Independent Director
COMPENSATION
$86K
AGE
56
TENURE
5.6 yrs

Bruce L. Carter

TITLE
Independent Director
COMPENSATION
$84K
AGE
75
TENURE
2.6 yrs

Rodney Lappe

TITLE
Director
COMPENSATION
$126K
AGE
63
TENURE
6.8 yrs

Mike Grey

TITLE
Independent Director
COMPENSATION
$77K
AGE
65
TENURE
4.4 yrs

Stephen Baylin

TITLE
Member of Scientific Advisory Board

George Demetri

TITLE
Member of Scientific Advisory Board
AGE
61

Lillian Siu

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Mar 19 Sell venBio Select Advisor LLC Company 18. Mar 19 20. Mar 19 -248,781 €67.42 €-16,418,896
21. Feb 19 Sell venBio Select Advisor LLC Company 20. Feb 19 20. Feb 19 -686,820 €64.25 €-44,131,344
22. Jan 19 Buy Tavistock Life Sciences Company 17. Jan 19 17. Jan 19 150,000 €54.45 €8,168,190
10. Jan 19 Sell Aaron Davis Individual 07. Jan 19 08. Jan 19 -50,000 €46.66 €-2,082,967
12. Jun 18 Buy venBio Select Advisor LLC Company 11. Jun 18 11. Jun 18 400,000 €32.90 €13,160,826
11. Jun 18 Buy Tavistock Life Sciences Company 07. Jun 18 07. Jun 18 193,050 €32.86 €6,342,744
X
Management checks
We assess Mirati Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mirati Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Details
Name: Mirati Therapeutics, Inc.
26M
Exchange: DB
Founded: 1995
$2,067,250,497
36,028,376
Website: http://www.mirati.com
Address: Mirati Therapeutics, Inc.
9393 Towne Centre Drive,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MRTX Common Shares Nasdaq Global Select US USD 29. Jun 2004
DB 26M Common Shares Deutsche Boerse AG DE EUR 29. Jun 2004
Number of employees
Current staff
Staff numbers
63
Mirati Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:20
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.